12:00 AM
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Newron, Zambon deal

The companies extended to May 13 the option exercise period for Zambon to license rights to Parkinson's disease therapy safinamide worldwide, excluding Asian territories. Upon exercise of the...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >